Enrolling now: quizartinib plus standard therapy for newly-diagnosed AML
Phase 3 MIDAS trial assesses MRD-driven approach to consolidation, maintenance therapy in myeloma
NCCN recommends pemivibart for BCL patients at risk of severe COVID-19
Early palliative care integration does not reduce MM patients’ healthcare utilization
Ingredient in popular energy drinks linked to leukemia growth

Join SOHO

Insider Podcast
About
Society Updates
- Society Updates
- Join SOHO
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Meeting News
Multimedia
- Roundtable Discussions
  - MDS Roundtable
  - MPN Roundtable
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

MPN News

Rio de Janeiro, Brazil - September 10, 2020: ANVISA, National Health Surveillance Agency, on smartphone screen. In Brazil, it exercises sanitary control over all products and services

Myeloproliferative Neoplasms Polycythemia Vera News

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

by SOHO Insider Editors
March 25, 2025
0 Comments

Myeloproliferative Neoplasms

Addition of ropeginterferon alfa-2b to standard PV care is cost effective

by SOHO Insider Editors
February 28, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms News Society Updates

Abstract submissions now open for SOHO 2025

by Leah Sherwood
February 14, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?

by SOHO Insider Editors
January 28, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Do driver mutations influence treatment outcomes in myelofibrosis?

by Leah Sherwood
January 10, 2025
0 Comments

Myeloproliferative Neoplasms Polycythemia Vera

Orphan drug designation granted to selective JAK2 inhibitor for treatment of polycythemia vera

by SOHO Insider Editors
January 6, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

by sohonews
November 8, 2024
0 Comments

Myeloproliferative Neoplasms

US veterans face high symptom burden, limited access to care in MPNs

by Leah Sherwood
June 7, 2024
0 Comments

Top Categories

Cellular Therapy

12

Leukemia

38

Lymphoma

38

Multiple Myeloma

28

Myelodysplastic Syndromes

13

Myeloproliferative Neoplasms

8

POPULAR NEWS

Leukemia , Lymphoma , Multiple Myeloma , Myelodysplastic Syndromes , Myeloproliferative Neoplasms , News , Society Updates

Abstract submissions now open for SOHO 2025

February 14, 2025

Leukemia , Acute Myeloid Leukemia , Myelodysplastic Syndromes

NCI’s myeloMATCH pushes the envelope in myeloid leukemia care

January 3, 2025

66th American Society of Hematology Annual Meeting & Exposition , Leukemia

Asciminib benefit-risk profile bests other TKIs in CML

December 10, 2024

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

MPN News

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Addition of ropeginterferon alfa-2b to standard PV care is cost effective

Abstract submissions now open for SOHO 2025

Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?

Do driver mutations influence treatment outcomes in myelofibrosis?

Orphan drug designation granted to selective JAK2 inhibitor for treatment of polycythemia vera

Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib

US veterans face high symptom burden, limited access to care in MPNs

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Enrolling now: quizartinib plus standard therapy for newly-diagnosed AML

Phase 3 MIDAS trial assesses MRD-driven approach to consolidation, maintenance therapy in myeloma

NCCN recommends pemivibart for BCL patients at risk of severe COVID-19

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

MPN News

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms